Overview

A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
A phase III study to assess the efficacy and safety of sublingual immunotherapy with STALORAL dust mites solution compared with placebo for reduction of asthma symptoms.
Phase:
Phase 3
Details
Lead Sponsor:
Stallergenes
Stallergenes Greer